• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Gene expression profiling and in vitro functional studies reveal RAD54L as a potential therapeutic target in multiple myeloma

by MM360 Staff | Jun 13, 2022 | Publications

Genes Genomics. 2022 Jun 11. doi: 10.1007/s13258-022-01272-7. Online ahead of print. ABSTRACT BACKGROUND: Current advances in the molecular biology of multiple myeloma (MM) are not sufficient to fully delineate the genesis and development of this disease. OBJECTIVE:...

Identification of Immune-Related Genes for Risk Stratification in Multiple Myeloma Based on Whole Bone Marrow Gene Expression Profiling

by MM360 Staff | Jun 13, 2022 | Publications

Front Genet. 2022 May 26;13:897886. doi: 10.3389/fgene.2022.897886. eCollection 2022. ABSTRACT Background: Multiple myeloma (MM) is characterized by abnormal proliferation of bone marrow clonal plasma cells. Tumor immunotherapy, a new therapy that has emerged in...

CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma

by MM360 Staff | Jun 13, 2022 | Publications

Oncoimmunology. 2022 May 31;11(1):2081415. doi: 10.1080/2162402X.2022.2081415. eCollection 2022. ABSTRACT Natural Killer (NK) cells are known for their high intrinsic cytotoxic capacity, and the possibility to be applied as ‘off-the-shelf’ product makes...

Epidemiology of Cancer Among Chronic Kidney Disease Patients Compared to The General Population

by MM360 Staff | Jun 13, 2022 | Publications

Gulf J Oncolog. 2022 May;1(39):7-15. ABSTRACT BACKGROUND: Kidney disease has a major effect on global health, both as direct cause of morbidity and mortality and as an important factor for other comorbid diseases including malignancy. Different studies report a higher...

Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience

by MM360 Staff | Jun 13, 2022 | Publications

Leuk Res Rep. 2022 May 30;17:100330. doi: 10.1016/j.lrr.2022.100330. eCollection 2022. ABSTRACT We report our retrospective analysis on 34 relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab based triplets. Twenty patients were females and 14...
« Older Entries
Next Entries »

Recent Content

  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Triplet regimen extends OS in relapsed or refractory multiple myeloma
  • Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
  • Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT